Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLemon bottle is an injectable fat-dissolving treatment marketed for localised fat reduction; Mounjaro (tirzepatide) is a prescription-only weight management medicine licensed by the MHRA and recommended by NICE for adults with obesity. These are fundamentally different interventions — one targets a specific area of the body via a cosmetic injection, the other works through the body's appetite and metabolic hormones — and the clinical evidence underpinning them sits in a completely different league. If you're weighing up lemon bottle and Mounjaro together, the most important starting point is understanding what each one is actually designed to do, and what the regulatory record says about it. Mounjaro is a prescription-only medicine: whether it is clinically appropriate for you is decided by a qualified prescriber, not by a price comparison.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 randomised controlled trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and tracked them for 72 weeks. Participants on the 15mg maintenance dose of tirzepatide lost an average of around 20–21% of their body weight alongside a reduced-calorie diet and increased physical activity. That is the kind of evidence base that regulators require before a medicine receives a marketing authorisation: independent peer review, a pre-registered protocol, a placebo comparator, and a trial population large enough to draw meaningful conclusions about both effectiveness and safety.
NICE reviewed this evidence and in December 2024 recommended tirzepatide for use in the NHS under specific eligibility criteria, set out in NICE technology appraisal TA1026. That recommendation does not exist in a vacuum: it followed a rigorous appraisal process that weighed clinical benefit against risk. No equivalent regulatory pathway has been completed for lemon bottle as a weight-loss intervention. Lemon bottle is a cosmetic treatment, sold and administered outside the medicines regulatory framework. That distinction is not a minor technicality, it determines whether the product's claims have been independently verified and whether its safety profile has been formally assessed at scale.
If you are exploring tirzepatide as a treatment option, that evidence base is the right place to start, and our tirzepatide bottle page explains what the medication packaging looks like and what to check when yours arrives.
Lemon bottle is a deoxycholic-acid-style injectable marketed for localised cosmetic fat reduction) typically small, defined areas such as under the chin or around the flanks. It is administered by cosmetic practitioners rather than through the medicines regulatory route, because it is classified as a cosmetic product rather than a medicine. That means the MHRA has not assessed lemon bottle for efficacy or safety in the way it assessed tirzepatide before granting its licence.
This does not make lemon bottle inherently dangerous, but it does mean that independent, regulatory-grade evidence for its effectiveness is thin. Cosmetic treatments of this type are not designed to address the metabolic and hormonal drivers of excess weight. They do not replicate the appetite-suppressing, gastric-slowing mechanism of a GLP-1 or dual GIP/GLP-1 medicine. Someone who has lost weight on Mounjaro and is left with a small area of stubborn fat might discuss a cosmetic procedure with a qualified practitioner, but that is a very different conversation from treating obesity itself.
For a broader look at what Mounjaro actually does in the body, the Mounjaro overview page covers the mechanism, the licensing, and the expected results in plain language.
The search that brings most people to this page is not purely academic, they want to know whether it is safe, or sensible, to have lemon bottle while already taking Mounjaro. That is a reasonable question and it deserves a careful answer rather than a dismissal. The short version: there is no specific published guidance from the MHRA or NHS England addressing this exact combination, because lemon bottle is not regulated as a medicine. What does exist is clear clinical common sense.
Mounjaro slows gastric emptying and can affect how the body absorbs certain substances. It also suppresses appetite, which means the metabolic context of someone on tirzepatide is different from someone who is not. Any procedure that introduces a substance into the body (even a cosmetic one) is worth discussing with the prescriber who manages your Mounjaro treatment before you book. That is not bureaucratic caution; it is how safe medicine works. Our page on whether lemon bottle is suitable while on Mounjaro goes into this specific question in more detail.
It is also worth being clear about what Mounjaro alone can achieve. In clinical trials, the average weight loss at the highest dose was substantial enough that many people find localised concerns resolve naturally over the course of treatment, without any additional procedure. Your prescriber is the right person to assess whether a cosmetic treatment alongside Mounjaro makes clinical sense for you personally, and the clinical team at nume is available to discuss questions like this as part of aftercare.
People making decisions about their weight and appearance are often navigating a crowded market (clinics, social media, before-and-after posts) where the word "evidence" gets used loosely. It is worth pausing on what that word means in practice.
For prescription medicines like Mounjaro, evidence means controlled trials in thousands of patients, independent peer review, regulatory scrutiny, and post-market surveillance including the MHRA's Yellow Card scheme. For cosmetic injectables, the bar is different: practitioners are regulated (in most cases) through local authority licensing, but the products themselves are not assessed for efficacy by the MHRA in the same way a medicine is.
None of this is a reason to dismiss cosmetic treatments outright. But it is a reason to be precise about what each intervention is for, and to involve your prescriber in any decisions that might intersect with your medication. If you're curious about how Mounjaro's clinical profile compares with other licensed weight-management options, the weight-loss treatment consultation page sets out what is available through a clinically supervised route.
One thing our prescribers are asked regularly: whether someone can combine a cosmetic session with their weekly injection on the same day. There is no hard rule against it, but they almost always suggest spacing them out, partly for comfort, partly to make it easier to attribute any post-procedure symptoms to the right cause. Simple, practical advice, the kind that is easy to miss if you're booking both on the same afternoon while the kids are at school. If you have ever been unsure whether you are looking at a genuine product, our tirzepatide logo page shows what authentic branded packaging should display.
For context on what Mounjaro treatment through a licensed private pharmacy typically involves in terms of cost, the Mounjaro price comparison page explains what a legitimate private prescription includes and why headline figures vary.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.